Friedl-Naderer Johanna
- SEC CIK
- 0001915598
In the past year, 6 open-market sale filings worth $43.4K and no purchases.
Current role at each company
- DYN Dyne Therapeutics, Inc.Chief Commercial Officeras of Sep 8, 2026
- VIR Vir Biotechnology, Inc.EVP & Chief Operating Officeras of Mar 7, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $43.4K
- 6 filings
- Net
- −$43.4K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Friedl-Naderer Johanna as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
DYN Dyne Therapeutics, Inc.
Chief Commercial Officer9 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 (view filing)4:15 PM ET | Sep 4-8 | 4 days | Friedl-Naderer JohannaChief Commercial Officer | SSale | −1.08K | $23.42 | −$25.4K | −0.7%152.9K after | 2 lots10b5-1 |
| Aug 17, 2026 (view filing)4:08 PM ET | Aug 13 | 4 days | Friedl-Naderer JohannaChief Commercial Officer | SSale | −226 | $26.28 | −$5.94K | −0.1%154.0K after | 10b5-1 |
| Jun 17, 2026 (view filing) | Jun 16 | 1 day | Friedl-Naderer JohannaChief Commercial Officer | SSale | −145 | $18.33 | −$2.66K | −0.1%154.2K after | 10b5-1 |
| May 14, 2026 (view filing) | May 13 | 1 day | Friedl-Naderer JohannaChief Commercial Officer | SSale | −228 | $18.36 | −$4.19K | −0.1%154.4K after | 10b5-1 |
| Mar 6, 2026 (view filing) | Mar 5 | 1 day | Friedl-Naderer JohannaChief Commercial Officer | SSale | −148 | $14.90 | −$2.21K | −0.1%154.6K after | 10b5-1 |
| Dec 5, 2025 (view filing) | Dec 5 | Same day | Friedl-Naderer JohannaChief Commercial Officer | SSale | −144 | $20.72 | −$2.98K | −0.2%94.7K after | 10b5-1 |
| Sep 8, 2025 (view filing) | Sep 4-5 | 4 days | Friedl-Naderer JohannaChief Commercial Officer | SSale | −1.04K | $13.29 | −$13.8K | −1.1%94.9K after | 2 lots10b5-1 |
| Jun 6, 2025 (view filing) | Jun 5 | 1 day | Friedl-Naderer JohannaChief Commercial Officer | SSale | −146 | $13.35 | −$1.95K | −0.2%95.9K after | 10b5-1 |
| Mar 13, 2025 (view filing) | Mar 13 | Same day | Friedl-Naderer JohannaChief Commercial Officer | SSale | −143 | $12.12 | −$1.73K | −0.1%96.1K after | 10b5-1 |
VIR Vir Biotechnology, Inc.
EVP & Chief Operating Officer1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 7, 2023 (view filing) | Mar 3 | 4 days | Friedl-Naderer JohannaEVP & Chief Operating Officer | SSale | −1.48K | $22.82 | −$33.8K | −1.0%148.5K after |